Kymera Therapeutics, Inc.
Advancing oral small-molecule degraders in immunology, led by a first-in-class STAT6 degrader.
Immunology & inflammation · Targeted protein degradation · Clinical (Phase 2b)
Advancing oral small-molecule degraders in immunology, led by a first-in-class STAT6 degrader.
Immunology & inflammation · Targeted protein degradation · Clinical (Phase 2b)